Socialización e interés en la política en jóvenes de Chile

El objetivo del artículo es discutir la relación entre socialización e interés por la política en jóvenes de Chile, desde las teorías de la socialización y la cultura política, que sostienen que las orientaciones de los individuos son adquiridas mediante procesos de relaciones con otros y con instituciones, de forma recíproca. A partir de la Encuesta Metropolitana de Comportamiento Político Juvenil (2012) aplicada a residentes -entre 18 y 25 años- del Gran Santiago, y a través de modelos de regresión logística, se verifica que el principal factor explicativo del interés por la política es informarse de esta temática con los amigos y amigas, destacando así la relevancia del contexto socializador.1. Introducción, -2. Cultura y socialización política. -3. Metodología. -4. Resultados. -5.Discusión. - Lista de referencias

Fragmentation of Andes-to-Amazon connectivity by hydropower dams

Andes-to-Amazon river connectivity controls numerous natural and human systems in the greater Amazon. However, it is being rapidly altered by a wave of new hydropower development, the impacts of which have been previously underestimated. We document 142 dams existing or under construction and 160 proposed dams for rivers draining the Andean headwaters of the Amazon. Existing dams have fragmented the tributary networks of six of eight major Andean Amazon river basins. Proposed dams could result in significant losses in river connectivity in river mainstems of five of eight major systems—the Napo, Marañón, Ucayali, Beni, and Mamoré. With a newly reported 671 freshwater fish species inhabiting the Andean headwaters of the Amazon (>500 m), dams threaten previously unrecognized biodiversity, particularly among endemic and migratory species. Because Andean rivers contribute most of the sediment in the mainstem Amazon, losses in river connectivity translate to drastic alteration of river channel and floodplain geomorphology and associated ecosystem services

Multiplication of arbuscular mycorrhizal fungi isolated from cocoa cultivated soils

La multiplicación de esporas de hongos micorrízicos arbusculares (HMA) es una limitante para las aplicaciones agrícolas como biofertilizantes. En el presente estudio se realizó la multiplicación masiva de HMA procedentes de fincas de cacao (Theobroma cacaoL.) en la región de San Martín, Perú, para optimizar su manejo y producción de esporas en condiciones ambientales controladas.Se diseñó un experimento en condiciones de invernadero, con undiseño completamente al azar, considerando tres fuentes de inoculo de HMA obtenidas en las provincias de Mariscal Cáceres, Lamas y Rioja,en dos periodos de tiempo (110 y 220 días) y dos cultivos hospedantes (maízy arroz). Este material fue mezclado con un volumen de arena y tres de tierra agrícola,que fueron colocadas en cajones; transcurrido elperiodo de tiempo se evaluóla población de esporas, colonización micorrícica, altura de la planta hospedante y peso seco de la parte aérea y de la raíz. La multiplicación de HMA a los 220 días, procedente de Mariscal Cáceres usando arrozcomo planta hospedante, demostró ser la más adecuada para la multiplicación delosHMA. El arroz actuó como un huésped adecuado y pudo multiplicar un mayor número de esporas.Se concluye queesta combinación puedeser utilizadacomo una metodología de propagación masiva de HMA debido a su gran capacidad para reproducirse.The multiplication of arbuscular mycorrhizal fungi (AMF) spores is a limitation for agricultural applications as biofertilizers. In the present study, a massive multiplication of AMF from cocoa farms (Theobroma cacao L.) in the San Martín region, Peru, was carried out to optimize their handling and spore production under controlled environmental conditions. The experiment was conducted under greenhouse conditions in a completely randomized design, considering three sources of AMF inoculum obtained in the provinces of Mariscal Cáceres, Lamas and Rioja, in two periods (110 and 220 days) and two host crops (maize and rice). This material was mixed with one volume of sand and three volumes of agricultural soil, which were placed in crates. At the end of the periods, the population of spores, mycorrhizal colonization, height of the host plant, and the dry weight of the aerial part and root were evaluated. Rice acts as a suitable host and multiplies a greater number of AMF spores. The treatment based on the mycorrhizal inoculum from Mariscal Cáceres multiplied with rice plants at 220 days, presented the highest population of spores. Therefore, it could be used as a methodology for massive propagation of AMF due to its great reproduction capacity.Fil: Vallejos Torres, Geomar. Universidad Nacional de San Martín Tarapoto; Perú. Universidad Católica Sedes Sapientiae; PerúFil: Tenorio Cercado, Miguel A.. Universidad Católica Sedes Sapientiae; PerúFil: Gaona Jimenez, Nery. Universidad Católica Sedes Sapientiae; PerúFil: Corazon Guivin, Mike A.. Universidad Nacional de San Martín Tarapoto; PerúFil: Luna, Javier Ormeño. Universidad Nacional de San Martín Tarapoto; PerúFil: Paredes, Christopher I.. Universidad Nacional de San Martín Tarapoto; PerúFil: Saavedra, Jorge. Universidad Nacional Autónoma de Alto Amazonas Unaaa; PerúFil: Tuesta, Juan C.. Universidad Nacional Autónoma de Alto Amazonas Unaaa; PerúFil: Tuesta, Oscar A.. Universidad Nacional Autónoma de Alto Amazonas Unaaa; PerúFil: Alguacil, M. M.. Universidad de Murcia; EspañaFil: Becerra, Alejandra Gabriela. Universidad Nacional de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto Multidisciplinario de Biología Vegetal. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas Físicas y Naturales. Instituto Multidisciplinario de Biología Vegetal; ArgentinaFil: Marín, César Alberto Aníbal. Universidad Santo Tomas, Santiago; Chil

Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications

Superparamagnetic iron oxide nanoparticles can providemultiple benefits for biomedical applications in aqueous environments such asmagnetic separation or magnetic resonance imaging. To increase the colloidal stability and allow subsequent reactions, the introduction of hydrophilic functional groups onto the particles’ surface is essential. During this process, the original coating is exchanged by preferably covalently bonded ligands such as trialkoxysilanes. The duration of the silane exchange reaction, which commonly takes more than 24 h, is an important drawback for this approach. In this paper, we present a novel method, which introduces ultrasonication as an energy source to dramatically accelerate this process, resulting in high-quality waterdispersible nanoparticles around 10 nmin size. To prove the generic character, different functional groups were introduced on the surface including polyethylene glycol chains, carboxylic acid, amine, and thiol groups. Their colloidal stability in various aqueous buffer solutions as well as human plasma and serum was investigated to allow implementation in biomedical and sensing applications.status: publishe

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

A database of freshwater fish species of the Amazon Basin

The Amazon Basin is an unquestionable biodiversity hotspot, containing the highest freshwater biodiversity on earth and facing off a recent increase in anthropogenic threats. The current knowledge on the spatial distribution of the freshwater fish species is greatly deficient in this basin, preventing a comprehensive understanding of this hyper-diverse ecosystem as a whole. Filling this gap was the priority of a transnational collaborative project, i.e. the AmazonFish project - https://www.amazon-fish.com/. Relying on the outputs of this project, we provide the most complete fish species distribution records covering the whole Amazon drainage. The database, including 2,406 validated freshwater native fish species, 232,936 georeferenced records, results from an extensive survey of species distribution including 590 different sources (e.g. published articles, grey literature, online biodiversity databases and scientific collections from museums and universities worldwide) and field expeditions conducted during the project. This database, delivered at both georeferenced localities (21,500 localities) and sub-drainages grains (144 units), represents a highly valuable source of information for further studies on freshwater fish biodiversity, biogeography and conservation